Patients with advanced basal cell carcinoma who are not suitable for surgery or radiotherapy, could benefit from Erivedge (vismodegib) which is available following conditional EMA authorisation for use in the UK and listing on the national
Basal cell carcinoma (BCC) is the most common form of skin cancer in the UK and is often found on the head and neck. Should it become advanced, by spreading to other sites (metastatic BCC), left to become large, or because of recurrence after treatment, it may become disfiguring and become inappropriate for standard treatments – surgery or radiotherapy (locally advanced BCCi).
Vismodegib, the first-of-a-kind once daily treatment, has been shown to shrink visible lesions (a cancerous change in tissue) in 47% of patients with locally advanced BCC inappropriate for surgery or radiotherapy (laBCCi) and shrink tumours in 33% of those with metastatic BCC (mBCC).
The advanced form of the disease affects up to 700 people a year in the UK,so this is a welcome advance and a potential new treatment option for patients with laBCCi and symptomatic mBCC.1,13 Specialist clinicians in England will be able to apply for vismodegib via the CDF which has added the drug and criteria for funding to its nationally approved list.
Dr John Lear, Consultant Dermatologist, Salford Royal NHS Foundation Trust said: “Advanced basal cell carcinoma can be a socially isolating and highly disfiguring disease that may impair patients’ facial structures and senses. Until now, there haven’t been any active treatment options available for patients for whom surgery or radiotherapy was not appropriate. Vismodegib, which has been shown to shrink tumours, is a welcomed new treatment option for patients with advanced BCC and should provide them with a promising new outlook.”
Vismodegib works by blocking the abnormal hedgehog cell signalling pathway. Abnormal activation of this pathway is responsible for cell growth and tumour development in more than 90% of all BCC cases. This was identified through work by Professor Phil Ingham and Cancer Research UK.
Dr Harpal Kumar, Chief utive of Cancer Research UK, said: “We are proud to have played a key role in the early development of this drug and we’re delighted that it has passed this regulatory hurdle and is approved for use in the UK. This drug is a major advance for the treatment of this disease, providing advanced basal cell carcinoma patients with a new treatment option. This is great news for patients and it’s thanks to the generosity of our supporters that we can invest in crucial early research which sparks advances like this.”
The ERIVANCE study investigated and showed that the median duration of progression-free survival for patients with laBCCi was 9.5 months when they were treated with vismodegib. The most common drug-related adverse events were muscle spasms, hair loss, altered taste sensation, weight loss, fatigue, nausea, decreased appetite and diarrhoea. In addition, vismodegib may cause embryo-foetal death or severe birth defects therefore vismodegib must not be given to a pregnant woman.
About advanced basal cell carcinoma
BCC is the most common skin cancer in the UK and the world and while for the majority of patients BCC lesions can be easily treated by surgery,in some patients (estimated at up to 700 patients in the UK) the disease progresses and becomes advanced. Where the disease becomes large or recurrent it can become inappropriate for surgery and radiotherapy (laBCCi) and may threaten key sensory organs such as the eye, ear or nose, as well as invading bone, muscles or nerves beneath the skin.
Vismodegib is indicated for the treatment of adults with locally advanced BCC that is inappropriate for surgery or radiotherapy and symptomatic metastatic BCC. Vismodegib targets the underlying molecular driver of BCC.Abnormal signalling in a cell growth pathway, known as the hedgehog pathway, is implicated in more than 90% of BCC cases and vismodegib is designed to selectively inhibit abnormal signalling in the hedgehog signalling pathway.